MHRA-cleared AI histopathology platform that quantifies breast cancer recurrence risk from routine tissue without molecular extraction.
Digistain is an MHRA-cleared and UKCA-marked AI-enabled histopathology platform that assesses breast cancer recurrence risk by analyzing routine FFPE tissue sections using optical scan technology that captures over 10,000 data points per biopsy. It produces a Digistain Prognostic Score with a 10-year recurrence likelihood to support MDT discussion and personalized treatment planning, without the molecular extraction required by traditional $4,000 genomic tests that take 2-8 months. The system integrates seamlessly with existing histopathology workflows and delivers results at a fraction of the cost and time. Digistain is a product of Digistain.